We found a significant increase in breast reconstruction in public health system in Brazil, and also a reduction in simple mastectomy and axillary lymphadenectomy.
Background: De novo metastatic breast cancer is seldomly encountered in patients visiting doctor’s clinics for the first time. This article reports a case of cervical/submandibular metastatic breast cancer treated with neoadjuvant endocrine therapy (NET) with anastrozole (ANA). Case description: We herein report on a patient affected by HR+, HER2−, and metastatic breast cancer treated with NET that presented after 6 months with the possibility of breast-conserving surgery due to clinical and radiological complete response, revealing after surgery pathological complete response. Conclusion: Even for patients with metastatic luminal breast cancer, NET with an aromatase inhibitor, especially ANA, is a good option for postmenopausal women with fewer side effects and allowing for breast-conserving surgery with less morbidity when comparing with chemotherapy and yet yielding good results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.